Market Alert: Trump Revives Trade War Playbook with Tariff Threats
Echo IQ Limited (ASX: EIQ), an Australian-based AI and medical technology firm, recently announced that its application for a Category III CPT code for its EchoSolv AS product in the U.S. was unsuccessful. Despite this outcome, the company remains optimistic and is actively revising its submission based on feedback from the American Medical Association (AMA). Echo IQ aims to reapply before the next submission deadline of June 11, 2025, targeting a potential code approval in September. The company emphasized that this development will not impact the current usage or integration of EchoSolv AS across U.S. sites. Additionally, Echo IQ continues to pursue FDA clearance for its EchoSolv HF product, expand partnerships with major hospital groups, and explore new licensing opportunities. CEO Dustin Haines reaffirmed confidence in their strategy and highlighted the continued progress on commercialization and product development efforts, ensuring momentum remains strong despite the temporary regulatory hurdle.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Jul 11, 2025
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
